Trials / Completed
CompletedNCT00002159
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Janssen, LP · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
Detailed description
Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole daily for 5 days or amphotericin B daily for 7 days. IV treatment is followed by consolidation with oral itraconazole for up to 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itraconazole | |
| DRUG | Amphotericin B |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002159. Inclusion in this directory is not an endorsement.